Oncology nurses must anticipate a disciplinary crossover between oncology and obstetrics to care for this unique subgroup of women with breast cancer.
Guidelines for managing chemotherapy-induced nausea and vomiting direct management toward risk assessment and prophylactic antiemetics.
Cancer cells hide from the body's natural defenses. This overview explains how immunotherapeutic strategies expose cancer cells to the immune system.
Head and neck cancer treatments have high morbidity rates. Newer options reduce morbidities and offer patients better quality of life after treatment.
The minimally invasive procedure provides effective, immediate relief from the pain of vertebral compression fractures due to multiple myeloma.
Advances in treatments, better risk assessment, and effective supportive care are leading to better outcomes for patients with lung cancer.
Understanding pain mechanisms and the types, triggers, and alleviating factors is needed to provide effective analgesia for patients with cancer.
This activity from myCME offers a review of groundbreaking molecular research and novel treatment options for patients with NSCLC.
Patients undergoing chemotherapy for hematologic cancers are at risk for this complication. The review can help you learn how to assess their risk.
A primer on what nurses need to know when scheduling items and services for patients participating in clinical trials.
Learn how patients' perceptions of health care can have a significant influence on the effectiveness of cancer care and patient education.
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
Signs and symptoms of venous thromboembolism in oncology patients should be heeded with prompt therapeutic and mechanical interventions.
This review describes the four major groups of leukemia, plus diagnostic tests and treatment regimens for each group.
Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.
VADs enable long-term IV therapy; however, the devices and their use pose a unique set of challenges for nurses.
CIPN is a debilitating adverse effect that can lead to reduced doses that hinder treatment effectiveness or early discontinuation of therapy.
Audiometric testing, awareness of the symptoms, and knowledge of which drugs are ototoxic can help protect young cancer patient's hearing.
Management and prognosis for patients with NHL depend on identifying the disease type. This review discusses the diagnoses and optimal treatments.
Identifying families at risk improves screening and counseling of patients at risk for hereditary nonpolyposis colorectal cancer.
Primary-care prevention of cervical cancer. To reduce the mortality and incidence of this disease, clinicians must be aware of the most recent vaccination and screening guidelines.
myCME.com offers over 50 oncology activities. Click here to view them all.
- Key discovery in understanding successes and failures of immunotherapy
- Researchers identify biological indicator of response to new ovarian cancer drug
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Reducing side effects of everolimus administration
- Navigation and survivorship: Rationalizing your program costs
- Monitoring psychosocial function in radiotherapy
- Comparison of medications for managing nausea and vomiting
- Comparison of constipation management medications
- Chemo- and immunotherapy combination is a promising treatment for pancreatic cancer
- High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone
- Hair Dyes and Cancer Risk (Fact Sheet)
- For bladder cancer, laparoscopic radical cystectomy effective at preventing recurrence
- Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
- Modifying lifestyle, HPV vaccine can help prevent anal cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|